Patient InformationlCommon QuestionslImportant Safety Information

Helpful Web Sites

Each of the links below will take you to a Web site to which our Privacy Policy does not apply. You are solely responsible for your interactions with such Web sites.

The following Web sites are neither owned by nor controlled by Pfizer. Pfizer is not responsible for the content or services on these sites.

Pulmonary Hypertension Association (PHA)

The mission of PHA is to seek a cure, to promote awareness and advocacy among the PAH community, and to provide hope, support, and education. The
organization sponsors scientific research and helps patients learn about new treatments and ways to cope with PAH.

801 Roeder Road, Suite 400
Silver Spring, MD 20910
800-748-7274 (Toll-free patient-to-patient helpline)
301-565-3004 (Administration)
E-mail: pha@phassociation.org
http://www.phassociation.org

Pulmonary Hypertension: The Complete Resource

This is an Internet resource for PAH-related information for patients, caregivers, and medical professionals. The site offers chat rooms, patient diaries, news and events, an online store, and links to other resources.
http://www.phcentral.org/

National Institutes of Health (NIH) Office of Rare Diseases

NIH’s Office of Rare Diseases Web site has a little information about pulmonary hypertension (PH) and offers a database of current PH clinical trials. The National Heart, Lung, and Blood Institute (NHLBI), which is part of NIH, sponsors and conducts research and training related to PH. The NHLBI site offers patient education as well as information about clinical trials and lifestyle.

National Institutes of Health Office of Rare Diseases

http://rarediseases.info.nih.gov

National Heart, Lung, and Blood Institute
http://www.nhlbi.nih.gov/index.htm

National Organization for Rare Disorders, Inc. (NORD)

NORD is a nonprofit federation of voluntary health organizations that helps people with rare diseases such as PH by supporting education, advocacy, and research.

National Institutes of Health Office of Rare Diseases

PO Box 1968
Danbury, CT 06813-1968
800-999-6673
203-797-9590
http://www.rarediseases.org

National Registry for Familial Primary Pulmonary Hypertension (FPPH)

Funded by NIH, this genetic research program is designed to collect information from families with hereditary PH, with the goal of learning the cause of the disease and developing new treatments. By identifying genes associated with PH, the aim is to find ways to modify the course of the disease and to learn about the relationship between PH and environmental factors. If you have more than one family member with PH, you are encouraged to enroll in the program. Confidentiality is protected.

800-288-0378
http://www.mc.vanderbilt.edu/root/vumc.php?site=vupphstudy

American Lung Association^®

The American Lung Association is the oldest voluntary health organization in the United States, with a national office and constituent and affiliate associations around the country. Founded in 1904 to fight tuberculosis, the American Lung Association today fights lung disease in all its forms, with special emphasis on asthma, tobacco control, and environmental health. The site offers news and information about lung diseases, treatment, support, advocacy, and environmental issues that affect public health.

61 Broadway, 6th Floor
New York, NY 10006
212-315-8700.
http://www.lungusa.org/

Next Section: Caregivers, Friends, and Family

Indication

REVATIO (sildenafil) is prescribed to treat pulmonary arterial hypertension (WHO Group I) to improve exercise ability and help lessen symptoms and slow down worsening changes in your physical condition. REVATIO has not been studied in patients taking bosentan.

Important Safety Information

If you take any medicines that contain nitrates (like nitroglycerin for chest pain) — daily or just once in a while — DO NOT take REVATIO.

REVATIO contains the same medicine as VIAGRA^® (sildenafil), which is used to treat erectile dysfunction (impotence). Do not take REVATIO with VIAGRA or other PDE5 inhibitors.

If you have ever had blockage of veins in your lungs, which is called pulmonary veno-occlusive disease, REVATIO is not recommended for you. If you feel dizzy, have chest pain, or discomfort while taking REVATIO, tell a doctor right away. Also, discuss your general health with your doctor, including if you ever had problems with low blood pressure or blood circulation. REVATIO is not recommended for patients taking ritonavir or antifungal medicines, such as ketoconazole and itraconazole. If you are taking REVATIO with bosentan or medicines like barbiturates, carbamazepine, phenytoin, efavirenz, nevirapine, rifampin or rifabutin, your doctor may adjust your dose. Also, tell your doctor if you are taking alpha-blockers for prostate or blood pressure problems.

Taking vitamin K antagonists (like coumadin or warfarin) with REVATIO may increase risk of nosebleeds. Tell your doctor if you take such medicines.

The safety of REVATIO is not known in patients with bleeding problems and those with stomach ulcers. If you have a condition like these, tell your doctor.

Sudden decrease or loss of hearing has been reported in people taking PDE5 inhibitors, including REVATIO. It is not possible to determine whether these events are related directly to the PDE5 inhibitors or to other factors. If you take a PDE5 inhibitor, including REVATIO, and experience a sudden decrease or loss of hearing, contact a doctor right away.

Men who took PDE5 inhibitors for erectile dysfunction had a sudden decrease or loss of sight in one or both eyes. It is not possible to know if these cases are related directly to these medicines or something else. If you take a PDE5 inhibitor, including REVATIO, and have a sudden decrease or loss of vision, call your doctor right away.

Erections that last for more than four hours may occur with all drugs in this class. Call a doctor right away if this happens to you. Erections that last more than six hours may lead to long-term loss of potency.

Patients who did not take part in the clinical trial were those who have had: a heart attack, stroke, or life-threatening irregular heartbeat within the last 6 months; chest pain; blood pressure greater than 170/110; eye discoloration; or patients on bosentan.

The most common side effects of REVATIO are nosebleeds, headache, upset stomach, flushing, and trouble sleeping.

At doses more than the approved 20 milligrams 3 times a day, some side effects increased. These included flushing, loose stools, muscle pain, and visual disturbances.

Please See Full Prescribing Information for REVATIO

Site MaplContact UslPfizer.comlPrivacy PolicylTerms of Use

RVU00115A. December 2009.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

This product information is intended only for residents of the United States.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.